retatrutide phase 2 trial obesity nejm 2023 Research Guide: What the Data Reported (2026) Phase 2 Trial of Retatrutide

That includes your doctor, a dietitian, a therapist, and your pharmacist

Unlike the SUSTAIN-6 study, this study excluded any patients who had pre-existing proliferative diabetic retinopathy (PDR) prior to initiation of tirzepatide and matched patients with their baseline level of DR or DME

Additionally, the medications weight loss effects contribute to improved blood pressure control

Blood pressure, lipids, and inflammatory markers all show substantial progress

J Clin Invest (2013) 123(6):27306

Safety profile Retatrutides most common side effects match what patients experience on semaglutide and tirzepatide: nausea, diarrhea, vomiting, and constipation